The clinical trial of Effects of 10-gram Collagen Protein Hydrolysate on Cardiometabolic Health
Maastricht University Medical Center is starting a new clinical trial of Effects of 10-gram Collagen Protein Hydrolysate on Cardiometabolic Health.
The effects of a 10g/day collagen hydrolysate for a period of 4 weeks on glycemic control and cardiovascular health in a parallel design study using overweight/ obese men and women who are likely to have a disturbed lipid and glucose metabolism and increased risk to develop cardiovascular disease and/or Type- 2 diabetes.
Food-derived bioactive peptides represent a source of health-enhancing components that have been reported to have cardiovascular health benefits in humans and may be incorporated in functional foods. Up till now studies using collagen hydrolysates particularly addressed issues around joint health, however, there are some preliminary indications that other health-related targets might be affected as well. We here propose to focus on the potential effects of collagen hydrolysates on glycemic control, and characteristics of the microcirculation, both important parameters for the assessment of future cardiovascular disease (CVD) risk.
The clinical trial started in May 26, 2021 and will continue throughout May 15, 2023.
Chronic glucose metabolism will be primary outcome measure. Measured by change in average daily glucose concentrations over a 15 hours period between waking up and going to bed 7:00-22:00 for three days, which is calculated based on the total area under the curve (tAUC) using a continuous glucose monitor.
The contacts and locations are the Maastricht University Medical Center, Maastricht, Netherlands. For more details: https://ichgcp.net/clinical-trials-registry/NCT05282641.
